NovaBridge Biosciences Net Income Loss

• NovaBridge Biosciences showed an increase of +89.3% in Net Income Loss from 2023 to 2024.
• This data is from NovaBridge Biosciences's annual report (Form 10-K), filed with the SEC on April 3, 2025.
• XBRL data for this metric is available from 2017 to 2024 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 8 years of available data (2017 to 2024), NovaBridge Biosciences's Net Income Loss has grown by 92.5%.
• Historical annual values: Fiscal year 2024: -$22.23 million | Fiscal year 2023: -$207.73 million | Fiscal year 2022: -$371.05 million | Fiscal year 2021: -$2.33 billion | Fiscal year 2020: $470.92 million | Fiscal year 2019: -$1.45 billion | Fiscal year 2018: -$402.83 million | Fiscal year 2017: -$298.24 million.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026